nach oben

Erschienen in:

02.04.2014 | Fortbildung

Ansatz der glutamatergen Modulation erweitert die Therapieoptionen

Antidepressivum Tianeptin

verfasst von: Prof. Dr. med. Hans-Peter Volz

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Antidepressivum Tianeptin wurde 1988 in Frankreich zugelassen, dann in einer Reihe europäischer Länder, vor allem in Mittel- und Osteuropa. Somit liegen zahlreiche Erfahrungen aus der klinischen Anwendung vor. Seit etwa eineinhalb Jahren ist die Substanz nun auch in Deutschland erhältlich. Diese Arbeit gibt einen kurzen Überblick über die präklinischen und klinischen Daten.

McEwen B, Chattary S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E. The neurobiological properties oaf Tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15: 237–249PubMedCentralPubMedCrossRef

Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88–109PubMedCrossRef

Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22: 15–26PubMedCrossRef

Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001; 98: 12796–12801PubMedCentralPubMedCrossRef

Magarinos AM, Deslandes A, McEwen BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999; 371: 113–122PubMedCrossRef

Watanabe Y, Gould E, Daniels DC, et al. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 1992; 222: 157–162PubMedCrossRef

Vouimba RM, Munoz C, Diamond DM. Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala. Stress 2006; 9: 29–40PubMedCrossRef

Diamond DM, Campbell A, Park CR, et al. Preclinical research on stress, memory, and the brain in the development of pharmacotherapy for depression. Eur Neuropsychopharmacology 2004; 14 (Suppl 5): S491–S495CrossRef

Rocher C, Spedding M, Munoz C, et al. Acute stress-induced changes in hippocampal/ prefrontal circuits in rats: effects of antidepressants. Cereb Cortex 2004; 14: 224–229PubMedCrossRef

10.

Shakesby AC, Anwyl R, Rowan MJ. Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. J Neurosci 2002; 22: 3638–3644PubMed

11.

Erecinska M, Silver IA. Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 1990; 35: 245–296PubMedCrossRef

12.

Zarate Jr CA, Du J, Quiroz J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003; 1003: 273–291PubMedCrossRef

13.

Reznikov LR, Grillo CA, Piroli GG, et al. Acute stress-mediated increases in extracellular glutamate leels in the rat amygdala: differential effects of antidepressant treatment. Eur J Neurosci 2007; 25: 3109–3114PubMedCrossRef

14.

Kole MH, Swan L, Fuchs E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur J Neurosci 2002; 16: 807–816PubMedCrossRef

15.

Svenningsson P, Tzavara E, Nomikos G, et al. Biochemical modulation of the AMPA receptor function by antidepressants [abstract no. S.04.02]. Eur Neuropsychopharmacol 2003; 13 (Suppl 4): S102CrossRef

16.

Robbins TW, Murphy ER. Behavioral pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 2006; 27: 141–148PubMedCentralPubMedCrossRef

17.

Jaffard R, Mocaer E, Poignant JC, et al. Effects of tianeptine on spontaneous alternation, simple and concurrent spatial discrimination learning and on alcohol-induced alternation deficits in mice. Behav Pharmacol 1991; 2: 37–46PubMedCrossRef

18.

Conrad CD, Lalea LA, Kuroda Y, et al. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 1996; 110: 1321–1334PubMedCrossRef

19.

Campbell AM, Park CR, Zoladz RR, et al. Pretraining administration of tianeptine, but not propranolol, protects hippocampus-dependent memory from being impaired by predator stress. Eur Neuropsychopharmacol 2008; 18: 87–98PubMedCrossRef

20.

Klasik A, Krysta K, Krupka-Matuszczyk I. Effect of tianeptine on cognitive functions in patients with depressive disorder during a 3-month observation. Psychiatrica Danubi 2011; 23: 18–22

21.

McEven BS, Olié JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 2005; 10: 525–537CrossRef

22.

Uzbay TI. Tianeptine: potential influences on neuroplasticity and novel pharmacological effects. Prog Neuropsychopharmacol Biol Psychiatry 2008; 15: 915–924CrossRef

23.

Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights in to the biomolecular basis of depression. Recent Pat CNS Drug Discov 2006; 1: 29–41PubMedCrossRef

24.

Mennini T, Mocaer E, Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol 1987; 336: 478–482PubMedCrossRef

25.

Fattaccini CM, Bolanos-Jimenez F, Gozlan H, Hamon M. Tianeptine stimulates uptake of 5-hydroxytriptamine in vivo in the rat brain. Neuropharmacology 1990; 29: 1–8PubMedCrossRef

26.

Malagie I, Deslandes A, Gardier AM. Effekcts of acute and chronic tianeptine administration on serotonin outflow in rats: comparison with paroxetine by using in vivo microdialysis. Eur J Pharmacol 2000; 403: 55–65PubMedCrossRef

27.

Pineyro G, Deveault L, de Montigny C, Blier P. Effect of prolonged administration of tianeptine on 5-HAT neurotransmission: an electrophysiological study in the rat hippocampus and dorsal raphe. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 119–125PubMed

28.

Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine. A review of ist use in depressive disorders. CNS Drugs 2001; 15: 231–259PubMedCrossRef

29.

Volz HP. Tianeptin–ein Antidepressivum mit “untypischem” Wirkmechanismus. Psychopharmakotherapie 2012; 19: 253–259

30.

Costa e Silva JA, Ruschel SI, Caetano D, et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 1997; 35: 24–29PubMedCrossRef

31.

Cassano GB, Heinze G, Lôo H, et al. A double- blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur Psychiatry 1996; 11: 254–259PubMedCrossRef

32.

Ginestet D. Efficacy of tianeptine in major depressive disorder with or without melancholia. Europ Neuropsychopharmacol 1997; 7: S341–S345CrossRef

33.

Guelfi JD, Pichot P, Dreyfus JF. Efficacy of tianeptine in anxious-depressed patients: results of controlled multicenter trial versus amitriptyline. Neuropsychobiology 1989; 22: 41–48PubMedCrossRef

34.

Invernizzi G, Aguglia E, Bertolino A, et al. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multi-center study vs. amitriptyline. Neuropsychobiology 1994; 30: 85–93PubMedCrossRef

35.

Lôo H, Malka R, Defrance R, et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 1988; 19: 79–85PubMedCrossRef

36.

Paes de Sousa M, Figueira L, Ferreira L, et al. Efficacy and acceptability of tianeptine in the long-term treatment of major depression. Double-blind trial: tianeptine vs clomipramine. Portugal: Servier Especialidades Farmacêticas, Lda. 2000. (Data on file).

37.

Svestka J, Synek O. Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled study [abstact]. Eur Neuropsychopharmacol 2000; 10 (Supp. 3): S252–S253CrossRef

38.

Kamoun A, Delalleau B, Ozun M. Can a serotonin uptake agonist bie an authentic antidepressant? Results of a multicenter, multinational therapeutic trial [in French]. Encephale 1994; 20: 521–525PubMed

39.

Chaby L, Grinsztein A, Weitzmann JJ, et al. Anxio-depressive disorders in menopausal and pre-menopausal women. Double-blind study of tianeptine vs. maprotiline [in French]. Presse Med 1993; 22: 1133–1138PubMed

40.

Ansseau M, Batallie M, Briole G, et al. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum Psychopharmacology 1996; 11: 293–298CrossRef

41.

Brion S, Audrain S, de Bodinat C. Episodes of severe depression in subjects over 70 years of age. Efficacy and acceptability of tianeptine and mianserine [in French]. Presse Med 1996; 25: 461–468PubMed

42.

Alby JM, Ferreri M, Cabanne J, et al. Efficacy of tianeptine (StablonTM) fort he treatment of major depression and dysthymia with somatic complaints. A comparative study versus fluoxetine (ProzacTM) [in French]. Ann Psychiatr 1993; 8: 136–144

43.

Novotný V, Faltus F. Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. Hum Psychopharmacol 2002; 7: 299–303CrossRef

44.

Lôo H, Saiz-Ruiz J, Costa-e-Silva JACE, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord 1999; 56: 109–118PubMedCrossRef

45.

Faltus F, Novotny V, Raboch J, Zucha I. Tianeptine fort he treatment of major depressive episode: a double-blind study versus fluoxetine. Eur Psychiatry 2000; 15 (Supp. 2): 419SCrossRef

46.

Guelfi JD, Bouhassira M, Bonett-Perrin E, et al. Study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice [in French]. Encephale 1999; 25: 265–270PubMed

47.

Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine. CNS Drugs 2002; 16: 65–75PubMedCrossRef

48.

Lepine JP, Altamura C, Ansseau M, et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study. Hum Psychopharmacol 2001; 16: 219–227PubMedCrossRef

49.

Szádóczky E, Füredi J. Efficacy and acceptability of tianeptine and sertraline in acute treatment phase of depression. Neuropsychopharmacologia Hungaria 2000; II (4): 171–177

50.

Kasper S, Olié JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 2002; 17 (Suppl 3): 331–340PubMedCrossRef

51.

Dalery J, Dagens-Lafont V, DeBodinat C. Efficacy of tianeptine vs placebo in the longterm treatment (16.5 months) of unipolar major recurrent depression [in French]. Encephale 1997; 23: 56–64PubMed

52.

Ducrocq F. Depression and sexual disorders [in French]. Encephale 1999; 25: 515–516PubMed

53.

Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19: 114–124PubMedCrossRef

54.

El-Shafey H, Atteya A, el-Magd SA, Hassanein A, Fathy A, Shamloul R. Tianeptine can be effective in men with depression and erectile dysfunction. J Sex Med 2006; 3: 910–917PubMedCrossRef

55.

Vandel P, Regina W, Bonin B, et al. Abuse of tianeptine. A case report [in French]. Encephale 1999; 25: 672–673PubMed

Titel: Ansatz der glutamatergen Modulation erweitert die Therapieoptionen
Antidepressivum Tianeptin
verfasst von: Prof. Dr. med. Hans-Peter Volz
Publikationsdatum: 02.04.2014
Verlag: Urban & Vogel
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 4/2014
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-014-0699-8

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Ansatz der glutamatergen Modulation erweitert die Therapieoptionen

Antidepressivum Tianeptin

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

2010 sanken die realen Erträge in Praxen

Epilepsie-Therapiemanagement in der Pädiatrie

Depression im Alter – Strategien für Diagnostik und Therapie

Epilepsie bei Menschen mit Intelligenzminderung

Wirksamkeit auf vielen Ebenen

Machen die Kartenleser den Online-Gang mit?

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein